一 | TOKYO -- The operator of the Fukushima Daiichi nuclear power plant said the discharge of the second batch of treated radioactive wastewater into the sea ended as planned on Monday, and International Atomic Energy Agency officials in Japan for their first safety and monitoring mission since the release began two months ago said “no issues” were observed.Fukushima Daiichi started releasing treated and diluted radioactive wastewater into the sea on Aug. 24. The operator, Tokyo Electric Power Company Holdings, said the release of a second, 7,800-ton batch of treated wastewater was completed, with its daily seawater sampling results fully meeting safety standards.A magnitude 9.0 quake on March 11, 2011, triggered a massive tsunami that destroyed the plant’s power supply and cooling systems, causing three reactors to melt and spew large amounts of radiation. Highly contaminated cooling water applied to the damaged reactors has leaked continuously into building basements and mixed with groundwater.The release of treated wastewater is expected to continue for decades. It has been strongly opposed by fishing groups and neighboring countries including South Korea, where hundreds of people have protested. China banned all imports of Japanese seafood the day the release began, badly hurting Japanese seafood producers, processors and exporters. Russia recently joined China in the trade restrictions.“I would say that the first two batches of releases went well. No issues were observed," Lydie Evrard, IAEA deputy director general and head of the department of nuclear safety and security, told a Tokyo news conference. She said she visited Fukushima Daiichi on Friday for a firsthand look.Evrard's visit came on the heels of a marine sampling mission by another IAEA team that included scientists from China, South Korea and Canada. She said all participants in that mission said their activity went well. She did not say whether Chinese scientists acknowledged the safety of the release.She said China has been involved in the IAEA safety task force since the beginning of the review that began two years ago and has participated in corroboration activities. The IAEA is aware of China’s concern and engaged with its authorities, Evrard said.Japanese Prime Minister Fumio Kishida, in his policy speech Monday, renewed his call for China to immediately lift its ban on Japanese seafood imports.During the Oct. 16-23 visit, the IAEA sampling team collected seawater, sediment and fish from near the plant and visited a marine laboratory near Tokyo that makes fish specimens for radiation analysis by institutions in and outside Japan, including the IAEA.During Evrard's visit, IAEA task force and Japanese officials are expected to discuss the safety of the ongoing discharge and their future mission plans, with a report expected by the end of the year. She said the discharge plan would be updated with new findings and data collected over the past two months.The IAEA, based on its two-year review of TEPCO's wastewater release plan, concluded in July that if it is carried out as planned, it will have a negligible impact on the environment, marine life and human health.Japan’s government and TEPCO say the discharge is unavoidable because wastewater storage tanks at the plant will be full next year. They say the water produced by the damaged plant is treated to reduce radioactivity to safe levels, and then diluted with massive amounts of seawater to make it much safer than international standards.TEPCO has said it plans to release 31,200 tons of treated water by the end of March 2024, which would empty only 10 tanks out of 1,000 because of the continued production of wastewater at the plant.。 8月13日，钱塘生物医药产业再迎里程碑时刻。位于杭州医药港的天境生物（TJ Biopharma）宣布，其产品注射用菲泽妥单抗（商品名：境斐®）正式获得国家药品监督管理局批准上市，用于与来那度胺和地塞米松联合用药，治疗既往至少接受过一线治疗的多发性骨髓瘤成年患者。这是该产品在全球范围内的首次获批。境斐®是一款靶向CD38的人源单克隆抗体，由天境生物在中国完成了多发性骨髓瘤适应症的临床开发与注册申报。今年4月，该企业与全球生物制药巨头渤健达成战略合作，渤健获得该产品大中华区独家权益，交易总金额达8.5亿美元。这一合作也标志着渤健实现了菲泽妥单抗全球权益的统一。根据协议，渤健将负责商业化，天境生物则依托其位于杭州医药港的GMP生产基地负责商业化供药。该基地已取得药品生产许可证，可实现核心产品的本土化稳定供应。“十年前，这些产品要等在国外上市了，再引进到中国重新做开发。目前，我们自主研发的产品把权益授权给海外公司。”天境生物董事长钱丽丽此前在接受央视《焦点访谈》采访时所说，从“引进来”到“授权出海”，钱塘创新药正完成角色的根本转换。境斐®的获批，也意味着今年以来钱塘已有3款1类创新药上市，数量位居全省第一。从“年年都有创新药”的目标提出，到如今多款产品密集落地，这一愿景正在钱塘一步步成为现实。截至目前，杭州医药港已集聚生物医药企业1800余家，累计4款1类创新药获批上市。另有138个创新药进入临床试验，数量居杭州市首位，其中14个药品处于临床三期。
Current article:http://lxqa.deshabisaoguonouzuo.cfd/news/20260826_4096.html
Published on:01:54:42
